EGFR and cancer: Clinical characteristics and outcomes and treatment patterns were assessed for 13 084 patients with NSQ cancer (75.4%; mean [SD] 62.2 [10.5] years; 6552 males [50.1%]) who were EGFR wild type and ALK wild type (WT subgroup) or had EGFR sequence variation (EGFR-positive subgroup) or ALK rearrangement (ALK-positive subgroup) and all 4751 patients with SQ cancer (mean [SD] age, 67.1 [8.6] years; 4427 males [93.2%]).